{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:23:51Z","timestamp":1787059431445,"version":"build-2736575974"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Project for Practical Application of Rare and Intractable Diseases, Japan Agency for Medical Research and Development (AMED)","award":["JP23ek0109665h0001"],"award-info":[{"award-number":["JP23ek0109665h0001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thirty years ago, in 1995, I proposed a fundamental treatment for Duchenne Muscular Dystrophy (DMD) using antisense oligonucleotides (ASOs) to induce exon skipping and restore dystrophin expression. DMD is a progressive and fatal muscular dystrophy, and the establishment of an effective therapy has been a pressing demand among patients worldwide. Exon-skipping therapy utilizing ASOs has garnered significant attention as one of the most promising treatments for DMD, stimulating global research and development efforts in ASO technology. Two decades later, in 2016, one ASO was conditionally approved by the U.S. FDA as the first DMD treatment. This review summarizes the current status and challenges of ASO-based exon-skipping therapies for DMD and explores the prospects of pseudoexon skipping using ASOs, which holds the potential for achieving a complete cure for DMD.<\/jats:p>","DOI":"10.3390\/ijms26031303","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T12:18:56Z","timestamp":1738585136000},"page":"1303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["30 Years Since the Proposal of Exon Skipping Therapy for Duchenne Muscular Dystrophy and the Future of Pseudoexon Skipping"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6747-7194","authenticated-orcid":false,"given":"Masafumi","family":"Matsuo","sequence":"first","affiliation":[{"name":"Graduate School of Science, Technology and Innovation, Kobe University, Kobe 657-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","article-title":"Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"JMA J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/352815a0","article-title":"Human dystrophin ex-pression in mdx mice after intramuscular injection of DNA constructs","volume":"352","author":"Acsadi","year":"1991","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0006-291X(90)92185-3","article-title":"A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene","volume":"170","author":"Matsuo","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI117693","article-title":"Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe","volume":"95","author":"Takeshima","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","article-title":"Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence","volume":"226","author":"Pramono","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0387-7604(01)00326-6","article-title":"Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient","volume":"23","author":"Takeshima","year":"2001","journal-title":"Brain Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1203\/01.pdr.0000215047.51278.7c","article-title":"Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy","volume":"59","author":"Takeshima","year":"2006","journal-title":"Pediatr. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications","volume":"13","year":"2007","journal-title":"RNA"},{"key":"ref_12","unstructured":"Ishikawa, Y., Miura, T., Nambu, N., Awano, H., Takeshima, Y., and Matsuo, M. (2025). A Duchenne muscular dystrophy patient treated with short-term exon skipping therapy 20 years ago exhibits superior cardiac function compared to untreated cases. Int. J. Mol. Sci., in submission."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/ddg100","article-title":"Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients","volume":"12","author":"Janson","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic Administration of PRO051 in Duchenne\u2032s Muscular Dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local Dystrophin Restoration with Antisense Oligonucleotide PRO051","volume":"357","author":"Janson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Aupy","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Krieg","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cell.2016.10.050","article-title":"Exon Skipping Therapy","volume":"167","author":"Young","year":"2016","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Assefa, M., Gepfert, A., Zaheer, M., Hum, J.M., and Skinner, B.W. (2024). Casimersen (AMONDYS 45\u2122): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040912"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s12325-024-02801-4","article-title":"Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy","volume":"41","author":"Vincik","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Cantara, S., Simoncelli, G., and Ricci, C. (2024). Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202402.1738.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Grainok, J., Pitout, I.L., Chen, F.K., McLenachan, S., Jeffery, R.C.H., Mitrpant, C., and Fletcher, S. (2024). A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063391"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14348\/molcells.2023.2172","article-title":"Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives","volume":"46","author":"Kim","year":"2023","journal-title":"Mol. Cells"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kuijper, E.C., Overzier, M., Suidgeest, E., Dzyubachyk, O., Maguin, C., P\u00e9rot, J.-B., Flament, J., Ariyurek, Y., Mei, H., and Buijsen, R.A. (2023). Antisense oligonucleotide-mediated disruption of HTT caspase-6 cleavage site ameliorates the phenotype of YAC128 Huntington disease mice. Neurobiol. Dis., 190.","DOI":"10.1016\/j.nbd.2023.106368"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: A phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2023.12.003","article-title":"The sense of antisense therapies in ALS","volume":"30","author":"Masrori","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus, A., Collin, R.W., Elgersma, Y., Lauffer, M.C., and van Roon-Mom, W. (2024). Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: The example of the Dutch Center for RNA Therapeutics. Ther. Adv. Rare Dis., 5.","DOI":"10.1177\/26330040241273465"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-56704-z","article-title":"Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe","volume":"29","author":"Goemans","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_38","first-page":"qxae051","article-title":"Medicaid spending and utilization of gene and RNA therapies for rare inherited condi-tions","volume":"2","author":"Odouard","year":"2024","journal-title":"Health Aff. Sch."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.crtox.2024.100182","article-title":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO","volume":"7","author":"Haque","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Faiella, M., Botti, G., Dalpiaz, A., Gnudi, L., Goyenvalle, A., Pavan, B., Perrone, D., Bovolenta, M., and Marchesi, E. (2024). In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Mus-cular Dystrophy Treatment. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16081023"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","article-title":"A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics","volume":"48","author":"Deprey","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"120398","DOI":"10.1016\/j.ijpharm.2021.120398","article-title":"Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides","volume":"599","author":"Dastpeyman","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102034","DOI":"10.1016\/j.omtn.2023.102034","article-title":"Exon 44 skipping in Duchenne muscular dystrophy: NS-089\/NCNP-02, a dual-targeting antisense oligonucleotide","volume":"34","author":"Watanabe","year":"2023","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/nat.2022.0063","article-title":"Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy","volume":"33","author":"Beekman","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JND-221648","article-title":"The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience","volume":"10","author":"Kirschner","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/nat.2023.0038","article-title":"Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy","volume":"33","author":"Engelbeen","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Doisy, M., Vacca, O., Saoudi, A., and Goyenvalle, A. (2024). Levels of Exon-Skipping Are Not Artificially Overestimated Because of the Increased Affinity of Tricyclo-DNA-Modified Antisense Oligonucleotides to the Target DMD Exon. Nucleic Acid Ther.","DOI":"10.1089\/nat.2024.0002"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102228","DOI":"10.1016\/j.omtn.2024.102228","article-title":"Deletion of miR-146a enhances therapeutic protein restoration in model of dystrophin exon skipping","volume":"35","author":"McCormack","year":"2024","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","article-title":"The elusive promise of myostatin inhibition for muscular dystrophy","volume":"33","author":"Wagner","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rybalka, E., Timpani, C.A., Debruin, D.A., Bagaric, R.M., Campelj, D.G., and Hayes, A. (2020). The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle. Cells, 9.","DOI":"10.20944\/preprints202010.0234.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/jcsm.13314","article-title":"A novel splice variant of the human MSTN gene encodes a myostatin-specific myostatin inhibitor","volume":"14","author":"Maeta","year":"2023","journal-title":"J. Cachex- Sarcopenia Muscle"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ppul.23215","article-title":"Cardiac phenotype determines survival in Duchenne muscular dystrophy","volume":"51","author":"Birnkrant","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCGEN.123.004384","article-title":"Novel Insights Into DMD-Associated Dilated Cardiomyopathy","volume":"16","author":"Wang","year":"2023","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Blain, A.M., Greally, E., McClorey, G., Manzano, R., Betts, C.A., Godfrey, C., O\u2019donovan, L., Coursindel, T., Gait, M.J., and Wood, M.J. (2018). Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-\/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198897"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Yamamura, N., Takakusa, H., Asano, D., Watanabe, K., Shibaya, Y., Yamanaka, R., Fusegawa, K., Kanda, A., Nagase, H., and Takaishi, K. (2024). Tissue distribution of renadirsen sodium, a dystrophin exon-skipping antisense oligonucleotide, in heart and diaphragm after subcutaneous administration to cynomolgus monkeys. Nucleosides Nucleotides Nucleic Acids, 1\u201317.","DOI":"10.1080\/15257770.2024.2389545"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.24306","article-title":"Pseudoexon activation in disease by non-splice site deep intronic sequence variation\u2014wild type pseudoexons constitute high-risk sites in the human genome","volume":"43","author":"Petersen","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1742-4658.2009.07520.x","article-title":"Alternative splicing: Role of pseudoexons in human disease and potential therapeutic strategies","volume":"277","author":"Dhir","year":"2010","journal-title":"FEBS J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JND-190431","article-title":"Pseudoexons of the DMD Gene","volume":"7","author":"Keegan","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhg.2010.49","article-title":"Mutation spectrum of the dystrophin gene in 442 Duchenne\/Becker muscular dystrophy cases from one Japanese referral center","volume":"55","author":"Takeshima","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10038-007-0163-0","article-title":"Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons","volume":"52","author":"Zhang","year":"2007","journal-title":"J. Hum. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ana.21290","article-title":"DMD pseudoexon mutations: Splicing efficiency, phenotype, and potential therapy","volume":"63","author":"Gurvich","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gatto, F., Benemei, S., Piluso, G., and Bello, L. (2024). The complex landscape of DMD mutations: Moving towards personalized medicine. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1360224"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Xie, Z., Tang, L., Xie, Z., Sun, C., Shuai, H., Zhou, C., Liu, Y., Yu, M., Zheng, Y., and Meng, L. (2020). Splicing Characteristics of Dystrophin Pseudoexons and Identification of a Novel Pathogenic Intronic Variant in the DMD Gene. Genes, 11.","DOI":"10.3390\/genes11101180"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lu, X., Han, C., Mai, J., Jiang, X., Liao, J., Hou, Y., and Cui, D. (2021). Novel Intronic Mutations Introduce Pseudoexons in DMD That Cause Muscular Dystrophy in Patients. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.657040"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Keegan, N.P., Wilton, S.D., and Fletcher, S. (2022). Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.806946"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/humu.24343","article-title":"Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy","volume":"43","author":"Waldrop","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e28020","DOI":"10.1016\/j.heliyon.2024.e28020","article-title":"A novel deep intronic variant introduce dystrophin pseudoexon in Becker muscular dystrophy: A case report","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase","volume":"30","author":"Leturcq","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Schwartz, S., Gal-Mark, N., Kfir, N., Oren, R., Kim, E., and Ast, G. (2009). Alu Exonization Events Reveal Features Required for Precise Recognition of Exons by the Splicing Machinery. PLOS Comput. Biol., 5.","DOI":"10.1371\/journal.pcbi.1000300"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Xie, Z., Liu, C., Lu, Y., Sun, C., Liu, Y., Yu, M., Shu, J., Meng, L., Deng, J., and Zhang, W. (2022). Exonization of a deep intronic long interspersed nuclear element in Becker muscular dystrophy. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.979732"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/nat.2021.0066","article-title":"Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene","volume":"32","author":"Leal","year":"2022","journal-title":"Nucleic Acid Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:22Z","timestamp":1760027182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031303"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031303","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}